BUZZ-West Pharma shares rise after completing credit facility refinancing
路透社2026/10/26 21:56October 26 - ** West Pharmaceutical Services (WST.N) shares rose 3.4% in after-hours trading, to $408.18
** According to regulatory filings, the company terminated its existing 2019 credit agreement after repaying the remaining $130 million outstanding debt
** West Pharmaceutical Services (link) signed a new five-year financing agreement, which includes a $750 million revolving credit facility and a $200 million term loan
** The new financing arrangement provides greater financial flexibility for working capital, capital expenditures, acquisitions, and other corporate purposes
** The company stated that the termination of its original credit agreement did not incur any prepayment penalties
** As of the close of the previous trading day, the stock had gained 43.5% so far this year
(To facilitate non-English speakers, Reuters has automatically translated its report into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translation and provides it only for reader convenience. Reuters accepts no responsibility for any harm or loss resulting from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Immunology and inflammation biotech company Bambusa (BBTX.US) prices IPO at $15-17 per share, aims to raise $150 million.
Bambusa Therapeutics plans to raise 150 millions USD by issuing 9.4 million shares at a price range of 15 to 17 USD per share.
The Bank of Japan’s price trend indicator rises above 3%, providing grounds for further rate hikes
The Bank of Japan's indicator for measuring underlying inflation has risen to its highest level in three years, far surpassing the bank's 2% target, providing grounds for authorities to continue raising interest rates.

$95 billion bet on AI! Meta (META.US) launches rare equity financing, while Goldman Sachs still maintains "Buy" rating
Meta announced a $95 billion equity financing, with NVIDIA, AMD, and Broadcom planning to subscribe $5 billion. Goldman Sachs reiterated its "buy" rating with a target price of $885.
Heimstaden Q3 Rental Income Rises to SEK 4.04 Billion